questionText: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and w
answerText: The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an asses...
heading: Myasthenia Gravis: Drugs